|Application ||WB, FC, E|
|Other Accession||NP_001091980.1, NP_659502.2|
|Calculated MW||50755 Da|
|Antigen Region||1-30 aa|
|Other Names||E3 ubiquitin-protein ligase pellino homolog 3, Pellino-3, 632-, PELI3|
|Target/Specificity||This PELI3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human PELI3.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PELI3 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates 'Lys-63'-linked polyubiquitination of IRAK1. Can activate AP1/JUN and ELK1. Not required for NF-kappa-B activation.|
|Tissue Location||Highly expressed in brain, heart and testis, and at lower level in kidney, liver, lung, placenta, small intestine, spleen and stomach. Isoform 1 is not expressed in lung|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Toll-like receptors (TLRs; see MIM 603030) and IL1R (IL1R1; MIM 147810) are part of the innate immune response aimed at mobilizing defense mechanisms in response in infection or injury. Pellino proteins, such as PELI3, are intermediate components in the signaling cascades initiated by TLRs and IL1R (Jensen and Whitehead, 2003 [PubMed 12874243]).
Xiao, H., et al. J. Biol. Chem. 283(21):14654-14664(2008)
Butler, M.P., et al. J. Biol. Chem. 280(30):27759-27768(2005)
Jensen, L.E., et al. J. Immunol. 171(3):1500-1506(2003)
If you have any additional inquiries please email technical services at email@example.com.